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Abstract
Background: Appetite and weight changes are core symptoms of Major Depressive Disorder (MDD), and
those with MDD are at increased risk of obesity, cardiovascular disease and metabolic disorders. Leptin
promotes satiety, with leptin dysregulation and resistance noted in obesity. However, the role of leptin in
weight changes in MDD is not established. This study investigates leptin levels in relation to appetite and
weight changes and problematic eating behaviours in MDD. Methods: Plasma leptin levels, psychopathology
and biometrics were compared between participants meeting DSM-5 diagnostic criteria for MDD (n = 63)
and healthy controls (n = 60). Depressed participants were also subcategorised according to increased,
decreased or unchanged appetite and weight. The Dutch Eating Behaviour Questionnaire and Yale Food
Addiction Scale were examined in a subset of participants with MDD. Results: Females with increased
appetite/weight had higher leptin levels than those with stable or reduced appetite/weight, however males
showed the opposite effect. Leptin levels were positively correlated with problematic eating behaviours. One
quarter of the depressed subset, all females, met the Yale criteria for food addiction, approximately double the
rates reported in general community samples. Limitations: The study is limited by a cross sectional design and
a small sample size in the subset analysis of eating behaviours. Conclusions: The results provide new
information about associations between leptin, sex-specific weight and appetite changes and problematic
eating behaviours, which may be risk factors for cardiovascular and metabolic diseases in MDD, particularly in
females. Future longitudinal research investigating leptin as a risk factor for weight gain in MDD is warranted,
and may lead to early interventions aimed at preventing weight gain in at-risk individuals.
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Background: Appetite and weight changes are core symptoms of Major Depressive Disorder 
(MDD), and those with MDD are at increased risk of obesity, cardiovascular disease and 
metabolic disorders. Leptin promotes satiety, with leptin dysregulation and resistance noted 
in obesity. However, the role of leptin in weight changes in MDD is not established. This 
study investigates leptin levels in relation to appetite and weight changes and problematic 
eating behaviours in MDD. 
Methods: Plasma leptin levels, psychopathology and biometrics were compared between 
participants meeting DSM-5 diagnostic criteria for MDD (n = 63) and healthy controls (n = 
60). Depressed participants were also sub-categorised according to increased, decreased or 
unchanged appetite and weight. The Dutch Eating Behaviour Questionnaire and Yale Food 
Addiction Scale were examined in a subset of participants with MDD. 
Results: Females with increased appetite/weight had higher leptin levels than those with 
stable or reduced appetite/weight, however males showed the opposite effect. Leptin levels 
were positively correlated with problematic eating behaviours. One quarter of the depressed 
subset, all females, met the Yale criteria for food addiction, approximately double the rates 
reported in general community samples. 
Limitations: The study is limited by a cross sectional design and a small sample size in the 
subset analysis of eating behaviours. 
Conclusions: The results provide new information about associations between leptin, sex-
specific weight and appetite changes and problematic eating behaviours, which may be risk 
factors for cardiovascular and metabolic diseases in MDD, particularly in females. Future 
longitudinal research investigating leptin as a risk factor for weight gain in MDD is 
warranted, and may lead to early interventions aimed at preventing weight gain in at-risk 
individuals. 
Keywords: leptin, Major Depressive Disorder, appetite, weight gain, obesity, food addiction 
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1. Introduction:  
 
The global prevalence of Major Depressive Disorder (MDD) is rising annually, with 
this rise currently being attributed to increasing stress, endocrine dysfunction, modern 
lifestyle characteristics and dietary patterns (Hidaka, 2012). Altered eating behaviours, and 
appetite and weight dysregulation, are central diagnostic criteria of MDD (American 
Psychiatric Association, 2013). MDD is a risk factor for obesity, cardiovascular disease and 
metabolic syndrome (Cassano & Fava, 2002; Penninx et al., 2013), with a key risk factor 
being increased appetite; which can occur in MDD (American Psychiatric Association, 
2013). Identifying biological and behavioural pathways between MDD and changes in 
appetite and weight could improve interventions. The hormone leptin is relevant due to its 
relationship with adiposity and role in satiety, however its relationship to MDD-related 
weight changes is not properly understood. 
There are bidirectional influences between MDD, appetite and weight dysregulation, 
as MDD increases the risk of becoming obese, and obese individuals are at an increased risk 
of developing MDD (Kloiber et al., 2007; Luppino et al., 2010). However, depressed 
individuals may experience either increases or decreases in their appetite and/or weight (e.g. 
Li et al., 2014; Paans et al., 2017); therefore, it is important to consider individual depressive 
symptom profiles in research relating to health risks. Increased appetite and weight gain are 
features of atypical MDD, a sub-type of MDD further characterised by hypersomnia, 
psychomotor slowing, increased mood reactivity and sensitivity to interpersonal rejection 
(American Psychiatric Association, 2013). Atypical MDD is further associated with higher 
body mass index (BMI; Lassere et al., 2014), higher instances of metabolic syndrome 
(Lamers, Beekman, van Hemert, Schoevers & Penninx, 2016b) and increased endocrine 
dysregulation (e.g. Gecici et al., 2005; Lamers et al., 2016a; Milaneschi et al., 2017). There 
are also indications that weight gain and increased appetite, while previously referred to as 
‘atypical’, are increasingly being identified as a ‘typical’ symptom of MDD (Privitera, 
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Misenheimer & Doraiswamy, 2013). Additionally, a large epidemiological survey indicated 
that the prevalence of MDD with atypical features was almost 40% higher than that of MDD 
without atypical features (Blanco et al., 2012). This apparent rise in MDD with weight gain 
may be associated with the increase of comfort foods in the environment (those high in fat 
and sugar), which people in emotional distress may seek out (Privitera et al., 2013).  
Problematic eating behaviours have also been noted in MDD, which are commonly 
measured using the Dutch Eating Behaviours Questionnaire (DEBQ; van Strien et al., 1986). 
These include Emotional eating, or increasing food intake in response to negative emotions 
as a form of coping mechanism; External eating, or increased food intake in response to 
external food cues, including the sight and smell of food; and Restrained eating, or 
deliberately restricting food intake to lose weight or prevent weight gain (van Strien et al., 
2016). More severe depressive symptoms are associated with higher emotional eating (van 
Strien et al., 2016), increased carbohydrate cravings (Christensen & Pettijohn, 2001), 
increased consumption of energy-dense foods in response to emotional distress (Konttinen et 
al., 2010) and increased food intake in response to internal and external food cues (Sevincer 
et al., 2017). Restrictive eating behaviours, and reduced food intake, have also been linked to 
depressive symptoms in previous studies (Polivy et al., 1978; Sevincer et al., 2017).  
Another approach to understanding overeating is the concept of food addiction, which 
can be measured using the Yale Food Addiction Scale (YFAS; Gearhardt et al., 2009). It has 
been proposed that food addiction forms part of a continuum consisting of varying degrees of 
overeating behaviours that range from normal eating patterns to obesity (Piccinni et al., 
2015). Food addiction is also associated with depressed mood, with one study reporting that 
obese individuals who met the YFAS criteria for food addiction displayed more severe 
depressive symptoms (Gearhardt et al., 2012). The prevalence of food addiction ranges from 
5-10% in the general population, and 15-25% in obese individuals (Meule & Gearhardt, 
2014). The preference for palatable foods, including those high in sugar, fat or carbohydrates 
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during periods of emotional distress (Lutter & Nestler, 2009; Hoch et al., 2015) has been 
attributed to their ability to reduce the psychological and physiological impact of stress (e.g. 
Dallman et al., 2003; Ulrich-Lai, 2016) and activate dopamine-based neural reward pathways 
(Gearhardt et al., 2011; Volkow et al., 2012), which can result in addiction-like behaviours; 
similar to alcohol or other psychoactive substances (e.g. Gearhardt et al., 2009; Piccinni et 
al., 2015). Food addiction is not yet recognised as a formal diagnosable disorder, and is 
currently defined as a substance-use disorder in the DSM-5 (American Psychiatric 
Association, 2013); however little is known about the relationships between addictive eating 
behaviours, leptin and MDD. 
 Leptin is a peptide hormone encoded by the ob gene secreted by adipocyte cells, with 
a critical role in regulating adipose tissue mass and energy balance as part of homeostasis 
(Lu, 2007). It has a fundamental role as an appetite suppressant during times of excess food 
consumption (Elmquist et al., 1998; Trayhurn et al., 1999), and is involved in weight 
regulation, where plasma leptin levels are released in proportion to adipose tissue mass 
(Maffei et al., 1995). However, although subcutaneous injection of leptin in lean and obese 
individuals may lead to decreased food intake and moderate weight loss (Heymsfield et al., 
1999), the use of leptin as a long-term weight loss strategy has been unsuccessful (Halaas et 
al., 1997; Widdowson et al., 1997; Heymsfield et al., 1999; Levin & Dunn-Meynell, 2002). A 
possible explanation for this is leptin resistance, which is characterised by high leptin levels 
but decreased leptin sensitivity (e.g. Pan et al., 2014). Leptin resistance has been proposed as 
a mechanism in the pathogenesis of obesity (Zigman & Elmquist, 2003; Ozsoy et al., 2014), 
with obese animals and humans being noted to have naturally elevated levels of leptin in the 
absence of food intake (e.g. Maffei et al., 1995).  
Leptin also moderates stress responses induced by the hypothalamic-pituitary-adrenal 
(HPA) axis. Leptin secretion has been demonstrated to inhibit corticosteroid production, and 
thereby suppressing stress adaptation responses (Bornstein et al., 1997; Roubos et al., 2012). 
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Failure of the HPA axis to execute appropriate stress responses may lead to the development 
of mental disorders such as MDD and anxiety (e.g. Blackburn-Munro & Blackburn-Munro, 
2001). In animal studies, chronic stress decreases plasma leptin levels (Lu et al., 2006) and 
insufficient circulating leptin is associated with MDD-like behaviours (e.g. Ge et al., 2013; 
Liu et al., 2017). Administration of leptin to rats after laboratory stressors reversed MDD-like 
behaviour; suggesting that leptin may also have antidepressant like efficacy (Kim et al., 2006; 
Hirano, Miyata & Kamei, 2007). The relationship between leptin and stress, including 
symptom severity, remains relatively unexplored, particularly in the context of MDD where 
increased stress is a key feature of the condition (American Psychiatric Association, 2013).  
Human studies comparing leptin levels in MDD have found inconsistent results, with 
either lower (e.g. Kraus et al., 2001; Westling et al., 2004; Atmaca et al., 2003) or elevated 
(e.g. Antonijevic et al., 1998; Jiménez et al., 2009; Morris et al., 2012) leptin levels overall 
between depressed and non-depressed individuals. In contrast, several studies (e.g. Häfner et 
al., 2012; Ozsoy et al., 2014) have identified no difference in leptin levels between depressed 
and non-depressed individuals; in some cases, even in the presence of appetite loss (Deuschle 
et al., 1996). No overall difference in leptin levels in individuals with MDD compared to 
controls was further supported by a recent large scale meta-analysis by Carvalho et al. 
(2014), however there were inconsistent results across the studies included. Studies 
comparing leptin levels across subtypes of MDD have also demonstrated inconsistent results. 
Individuals with typical/melancholic MDD often demonstrate lower leptin levels compared to 
controls and individuals with atypical MDD, with the latter demonstrating consistently higher 
leptin levels overall (e.g. Gecici et al., 2005; Lamers et al., 2016a, Milaneschi et al. 2017). 
The variability of these results may be due to heterogeneity in appetite and weight change 
symptoms in MDD, and subsequent alterations in leptin levels. Further, differences in leptin 
levels between subtypes of MDD with increased or decreased appetite/weight may have been 
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masked in previous research, as symptom subtypes are frequently combined in previous 
studies. 
Further, the methods of classifying atypical MDD symptoms have differed between 
studies. Some studies have used solely DSM based criteria (e.g. Gecici et al., 2005; Lassere 
et al., 2014), and others have used latent class analysis based on a combination of 
questionnaire and diagnostic interview responses. The questionnaires and interviews used to 
measure depressive symptoms for latent class analysis vary, with measures such as the 
Inventory of Depressive Symptoms (IDS-SR; Rush et al., 1996), Hamilton Depression Rating 
Scale (HDRS; Hamilton, 1960) and the Composite International Diagnostic Interview (CIDI; 
World Health Organisation, 1997) being used (e.g. Lamers et al., 2016a, 2016b; Milaneschi 
et al., 2017). However, it has been noted that latent class analysis classifications of MDD 
symptoms do not align completely with DSM-based criteria (Lamers et al., 2016a; 2016b). 
Therefore, the inconsistent methods may be a potential confounding factor in these studies. 
Further, not all atypical symptoms have been found to correlate with leptin levels; of the 
atypical symptoms, changes in weight gain and appetite are most strongly correlated with 
leptin levels (Lamers et al., 2016a; Milaneschi et al., 2017). This suggests that changes in 
appetite/weight may provide a clearer means of subtype classification for the purposes of 
examining connections between leptin, MDD, appetite and weight gain than the broader 
criteria of atypical MDD. 
Some studies have indicated a sexual dimorphism in leptin levels, with females 
having higher leptin levels than males (Antonijevic et al., 1998; Rubin et al., 2002). 
However, other studies have indicated no difference in leptin levels between sexes (e.g. 
Hillemacher et al., 2006; Atmaca et al., 2003). However, there may be interactions between 
sex and depression status in terms of leptin (Milaneschi et al., 2012; Haleem et al., 2017). 
Depressed women are more prone to weight gain and obesity than males (e.g. Sutin & 
Zonderman, 2012; Grundy et al., 2014). It is therefore pertinent to investigate leptin levels by 
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sex and MDD status. Further, examining appetite and weight symptom presentations by sex 
is also important in order to elucidate specific relationships between leptin and MDD 
symptom profiles. 
Due to its role in adiposity, leptin has consistently been correlated with body mass 
index (BMI) and waist circumference (e.g. Jow et al., 2006; Morris et al., 2012; Chen et al., 
2016). Leptin has also been related to risk factors for cardiovascular disease, with elevated 
leptin levels associated with higher systolic and diastolic blood pressure (e.g. Beltowski, 
2006; Ma et al., 2009) and heart rate (Brydon, 2011). This is particularly relevant to MDD 
because of its associations with obesity, cardiovascular disease and metabolic syndrome 
(Cassano & Fava, 2002; Penninx et al., 2013). 
In summary, further research is needed to better understand relationships between 
leptin levels, eating behaviours and changes in appetite and weight in MDD, and whether 
these differ by sex. Previous leptin studies have also not measured stress severity, which is 
relevant considering the role of leptin in moderating activity of the HPA axis. While 
relationships between leptin, BMI and waist circumference have been previously noted, 
relationships between leptin and cardiovascular disease risk factors such as blood pressure 
and heart rate have not yet been sufficiently explored in MDD. Further, while leptin has been 
linked to depressed mood (Westling et al., 2004; Ozsoy et al., 2014), and depressed mood has 
been linked to problematic eating behaviours (e.g. van Strien et al., 2016; Sevincer et al., 
2017), there is no direct research examining the relationships between food addiction and 
problematic eating behaviours in MDD, particularly in relation to leptin levels. An 
understanding of these unexplored relationships may elucidate relationships between MDD 
and other chronic health conditions. 
 In the current study, plasma leptin levels, biometrics, and psychometric measures of 
depression, anxiety and stress were compared between individuals with MDD and healthy 
controls. Depressed participants were sub-categorised to compare those with increased, 
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reduced or unchanged appetite and weight, by sex. Further, relationships between leptin, 
problematic eating behaviours and food addiction were examined in a subset of depressed 
participants. In line with previous literature, it was predicted that: 
1. Leptin levels would not differ significantly between depressed and non-depressed 
participants overall. 
2. Depressed participants with increased appetite/weight would demonstrate higher 
leptin levels than depressed participants with decreased or unchanged appetite/weight, 
with effects being greater in females; 
3. Psychometric indices of depression severity, anxiety and stress would positively 
correlate with leptin levels; 
4. Biometric indices of obesity and cardiovascular disease risk factors (including BMI 
and blood pressure), would positively correlate with plasma leptin levels, and; 







One hundred and twenty-three (123) adults aged between 18 and 69 years (M = 31.87 
± 12.88 years; 70 female, 53 male) participated in the study. 63 participants met the 
diagnostic criteria for MDD, as confirmed by the Mini International Neuropsychiatric 
Interview; a valid semi-structured interview based on the DSM-5 designed to assess for 
psychiatric conditions (MINI; Sheehan et al., 1998; Lecrubier et al., 1997). Participants were 
recruited by media advertisements, notices and newsletters at the university.  
Depressed participants were required to not be receiving any current or recent 
psychological or medication-based treatment for MDD. The 60 control participants had no 
history of diagnosed psychiatric disorders. Exclusion criteria across both groups were use of 
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corticosteroids, neurological illness and substance use disorders. Participants were asked to 
provide details of all medical conditions, medications and substance use. Eight participants 
reported a diagnosis of an insulin dysregulation disorder, including diabetes and polycystic 
ovarian syndrome. No participants had diagnosed eating disorders. No participants were 
current smokers. The study was approved by the local ethics committee, and all participants 




Data collection occurred at the University Clinical Research Trials Unit. All 
appointments were scheduled between 9:00am and 11:00am to control for diurnal variations 
in hormones. On arrival at the clinical trials unit, depressed participants were interviewed 
using the Mini Neuropsychiatric Interview, version 7.0.2 for DSM 5 (Sheehan, 2015) to 
confirm MDD diagnoses and symptoms, including weight and appetite changes. Control 
participants were also asked whether they had experienced recent changes in weight or 
appetite. 
After provision of informed consent, height, weight, blood pressure and heart rate 
were taken. Waist circumference was measured in the depressed participants only. Following 
the provision of a non-fasting 10ml blood sample obtained by an experienced phlebotomist, 
participants then completed the Depression, Anxiety and Stress Scale; a 21 item self-report 
questionnaire assessing depression, anxiety and stress severity (DASS-21; Lovibond & 
Lovibond, 1995). The DASS-21 total score has high internal consistency (Cronbach’s a = 
.94; Gloster et al., 2008) The three subscales of the DASS-21 have demonstrated high 
internal consistency also (Cronbach’s a = .96 for depression, .89 for anxiety, .93 for stress; 
Brown, Chorpita, Korotitsch & Barlow, 1997). 
During the study, when asked about appetite and weight changes, depressed 
participants frequently volunteered that they experienced loss of control around food cues 
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and increased emotional eating. Therefore, we obtained ethical approval to administer 
additional questionnaire measures to the remaining participants, to investigate eating 
behaviours in more detail, as an exploratory study. The Dutch Eating Behaviours 
Questionnaire (DEBQ; van Strien et al., 1986) and the Yale Food Addiction Scale (YFAS; 
Gearhardt et al., 2009) were administered to a subset of 33 depressed participants (20 female, 
13 male) in order to investigate eating behaviours in the context of appetite and weight 
dysregulation in MDD. The DEBQ measures problematic eating styles, including restrained, 
emotional and external eating behaviours; with each of the three subscales demonstrating 
high internal consistency (Cronbach’s a = .93 for restrained, .93 for emotional, .80 for 
external eating; van Strien et al., 1986). The YFAS measures food addiction related 
behaviours, including withdrawal symptoms and loss of control around food cues; with the 
total YFAS score also demonstrating high internal consistency (Cronbach’s a = .86; 
Gearhardt et al., 2009). 
 
2.3 Data and Statistical Analysis 
 
Immediately following blood collection, blood samples were spun in a centrifuge at 
4°C, at 2800rpm for 10 minutes. Plasma was immediately stored in a -80°C freezer until 
analysis. Plasma leptin levels were measured using a standard ELISA (Abcam, Cambridge, 
United Kingdom) testing kit. The intra- and inter-assay coefficients of the ELISA were <10% 
and <12% respectively. 
Statistical analysis was conducted using ‘Statistical Package for the Social Sciences’ 
(SPSS, Version 23). A two-way factorial analysis of variance (ANOVA) was used to test for 
differences in the leptin levels, with the between subjects factors being Diagnosis (control, 
depressed) and Sex (male, female), and Age and BMI as covariates. A second two-way 
factorial ANOVA was used to test for differences in leptin levels as a function of appetite and 
weight changes, with the between subjects factors being Appetite and Weight Categories 
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(increased, decreased, no change) and Sex (male, female), with Age and BMI as covariates. 
Pearson’s correlation coefficients and Spearman’s rank correlations were used to determine 
relationships between the variables as appropriate. Post-hoc analyses were conducted using 




3.1 Biometric and Psychometric Data 
 
Biometric and psychometric data are displayed in Table 1. Diagnostic groups did not 
differ significantly in age. In terms of sex distributions, there were 35 females in both the 
MDD and control groups, 25 males in the control group and 28 males in the MDD group. The 
sex distributions between groups were not significant (c2 (2, N = 123) = .097, p = .076).  
Systolic blood pressure was higher in males (M = 135.38, SD = 12.92) than females 
(M = 117.04, SD = 11.64; F(1, 119) = 68.69, p < .001, partial η2 =.366). Diastolic blood 
pressure was also higher in males (M = 80.11, SD = 11.43) than females (M = 75.63, SD = 
9.24; F(1, 119) = 5.52, p = .020, partial η2 = .044). No significant effects for Diagnosis or 
interaction effects were identified for other biometric data. 
Depressed participants scored significantly higher on each of the Depression, Anxiety 
and Stress subscales of the DASS compared to controls (Depression: M = 23.21, SD = 9.38 
versus M = 6.17, SD = 7.43, F(1, 119) = 117.59, p < .001, partial η2 = .497; Anxiety: M = 
13.59, SD = 10.65 versus M = 4.60, SD = 5.56, F(1, 119) = 30.70, p < .001, partial η2 = .205;  
Stress: M = 21.90, SD = 9.60 versus M = 10.30, SD = 7.97; F(1, 119) = 49.99, p < .001, 






Table 1:  
 Means and standard deviations for biometric and psychometric data, by Diagnosis and Sex (total n = 123; MDD and control participants).  
 
Note: DASS = Depression, Anxiety and Stress Scale.  
a * a < .05, ** a < .01. 
 
  Sex Diagnosis 
Variable  Male Female Effect Control Depressed Effect 
  M (SD) M (SD) p M (SD) M (SD) p 
 Sample Size (n) 53 70 - 60 63 - 
Biometrics Age (years) 33.94 (14.23) 30.30 (11.61) .134 31.83 (10.98) 31.90 (14.55) .764 
 Weight (kg) 84.18 (14.60) 70.15 (17.32) < .001** 74.53 (16.95) 77.78 (18.16) .476 
 BMI (kg/m2) 26.52 (4.56) 25.57 (5.85) .323 25.13 (4.49) 26.77 (5.95) .147 
 Systolic Blood Pressure (mmHg) 135.38 (12.92) 117.04 (11.64) < .001** 126.40 (14.27) 123.56 (16.01) .153 
 Diastolic Blood Pressure (mmHg) 80.11 (11.43) 75.63 (9.24) .020* 76.83 (9.86) 78.25 (10.99) .422 
 Heart Rate (bpm) 72.68 (13.68) 73.59 (10.40) .693 73.29 (12.31) 73.13 (11.53) .946 
Psychometrics DASS Depression 14.98 (11.55) 14.83 (12.45) .856 6.17 (7.43) 23.21 (9.38) < .001** 
 DASS Anxiety 8.79 (8.50) 9.51 (10.47) .580 4.60 (5.56) 13.59 (10.65) < .001** 
 DASS Stress 15.77 (9.81) 16.60 (11.14) .495 10.30 (7.97) 21.90 (9.60) < .001** 
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3.2 Leptin Results 
 
Four participants (2 MDD, 2 controls) did not provide a blood sample, so data from a 
total of 119 participants were included in the leptin analysis. There were eight univariate 
outliers in the leptin data detected using boxplot diagrams, with their plasma leptin 
concentration being greater than two standard deviations above the mean (M = 142.97, SD = 
204.48). All outlier values belonged to depressed participants who reported insulin 
dysregulation disorders. Preliminary statistical analyses were conducted with and without the 
outliers. These initial results were similar, however when the outliers were removed a higher 
effect of leptin in MDD overall compared to healthy controls was no longer present. In order 
to eliminate the possibility of a potential confounding effect of insulin dysregulation on the 
leptin data, these outliers were excluded from subsequent analyses and only results without 
outliers are henceforth only reported. 
Preliminary inspection of the distribution of the raw leptin data from the remaining 
111 participants indicated a positively skewed distribution (skewness = 3.19, SE = .22). In 
line with previous human studies (e.g. Häfner et al., 2012; Milaneschi et al., 2012) the raw 
leptin data were natural-log transformed. Means and standard deviations for raw leptin and 
log-leptin values are displayed in Table 2 according to Diagnosis and Sex. 
After accounting for age and BMI as potential covariates, log-leptin values did not 
differ significantly overall between participants with MDD compared to controls (F(1, 111) = 
1.99, p = .161, partial η2 = .019). Females (M = 4.70, SD = 1.16) had significantly higher log 
leptin values than males (M = 3.15, SD = 1.54 F(1, 111) = 81.47, p < .001, partial η2 = .438). 
Age was identified as a significant covariate (F(1, 111) = 4.43, p = .038, partial η2 = .040), as 
was BMI (F(1, 111) = 73.86, p < .001, partial η2 = .413). 
The interaction between Diagnosis and Sex was significant (F(1, 111) = 4.99, p = 
.028, partial η2 = .045), with depressed males (M = 3.43, SD = 1.40) having higher log-leptin 
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levels than control males (M = 2.82, SD = 1.66). Leptin levels did not differ significantly 
between depressed (M = 4.86, SD = 1.21) and control females (M = 4.56, SD = 1.12) overall. 
 
Table 2:  
Means and standard deviations for raw and log-transformed leptin data, by Diagnosis and Sex 
(total n = 111; MDD and control participants). 
 
 
Note: significance noted for log-transformed data only.  
a * a < .05, ** a < .001. 
 
 
3.3 Analysis by Appetite and Weight Change Groups 
 
The 111 participants were classified according to whether they reported increased (n 
= 19, all depressed), reduced (n = 20, all depressed) or unchanged appetite/weight (n = 72, 12 
depressed, 60 controls) from the clinical interview. No controls reported significant changes 
in their appetite/weight, whereas participants with MDD reported either increased, decreased 
or unchanged appetite/weight. One way ANOVAs indicated no significant differences in 













  n M (SD) M (SD) p p 
Diagnosis 
Control 58 106.31 (104.96) 3.85 (1.61) 
.161 
 
Depressed 53 149.42 (226.30) 4.14 (1.48) 
.028* 
Sex 
Males 51 54.36 (63.95) 3.15 (1.54) 
< .001** 
Females 60 188.54 (211.59) 4.70 (1.16)  
Covariates 
Age (years) - - - .038* - 
BMI (kg/m2) - - - < .001** - 
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Table 3: 
Means and standard deviations for biometric data, by appetite/weight categories. (total n = 
111; MDD and control participants). 
 
  Increases Decreases Unchanged p 
  Mean (SD) Mean (SD) Mean (SD)  
 Sample Size (n) 19 20 72 - 
Biometrics Age 34.95 (17.21) 29.60 (11.53) 32.15 (11.91) .425 
 Weight 79.01 (19.67) 76.00 (15.82) 74.91 (15.88) .618 
 BMI 27.52 (5.75) 25.56 (4.64) 25.30 (4.41) .174 
 Systole 121.95 (15.01) 122.00 (15.41) 126.53 (13.88) .303 
 Diastole 78.35 (9.04) 76.60 (13.69) 77.28 (9.50) .861 
 Heart Rate 73.65 (11.84) 70.15 (9.33) 73.21 (12.19) .544 
 
a Indicates significant differences compared to the ‘Increased’ group. 
* a < .05, ** a < .01. 
 
The two-way ANOVA with Appetite/Weight categories (increased, decreased, no 
change) and Sex (male, female) as between group factors, with Age and BMI as covariates 
(Table 4), indicated that leptin values did not differ significantly across appetite/weight 
presentations (F(2, 111) = .11, p = .900). However, the interaction between Appetite/Weight 
categories and Sex was significant (F(2, 111) = 3.53, p = .033, partial η2 = .064). Females 
with increased (M = 5.20, SD = .87) or unchanged (M = 4.64, SD = 1.12) appetite/weight had 
higher log-leptin values compared to females with decreased appetite/weight (M = 4.16, SD = 
1.53). This pattern was the opposite in males, as those with decreased appetite/weight (M = 
3.65, SD = 1.69) had higher log-leptin values than males with increased (M = 3.31, SD = 
0.99) or unchanged (M = 2.94, SD = 1.56) appetite/weight.  
Leptin values were again significantly higher for females (M = 4.70, SD = 1.16) 
compared to males (M = 3.15, SD = 1.54 F(1, 111) = 36.90, p < .001, partial η2 = .264). BMI 
was a significant covariate (F(1, 111) = 69.55, p < .001, partial η2 = .578), however age as a 




Table 4:  
Means and standard deviations for raw and log-transformed leptin data, by Appetite/Weight 
Categories and Sex (total n = 111; MDD and control participants). 
 
 
Note: significance noted for log-transformed data only.  
a * a < .05, ** a < .001. 
 
 
Weight correlated positively with systolic (r(111) = .461, p < .001) and diastolic 
(r(111) = .383, p < .001) blood pressure. BMI also correlated positively with systolic (r(111) 
= .257, p = .006) and diastolic (r(111) = .390, p < .001) blood pressure. Further, BMI was 
positively correlated with weight (r(111) = .877, p = < .001). Log-leptin values correlated 
positively with BMI (r(111) = .449, p < .001), but were negatively correlated with systolic 
blood pressure, (r(111) = -.240, p = .011). No significant correlations were identified between 
log-leptin values, the remaining biometric measurements and DASS subscales. 
 
3.4 Subset Analysis of Eating Addiction and Eating Behaviours in MDD 
 
As a further exploratory analysis, waist circumference was measured, and the Dutch 
Eating Behaviours Questionnaire (DEBQ) and the Yale Food Addiction Scale (YFAS) were 
administered to 33 participants recruited to the MDD group (n = 33). Of these 33 participants, 
15 reported increased, 11 decreased and 7 unchanged appetite/weight. Between-groups 
analyses based on appetite/weight presentations were not performed due to small cell sizes.   
Variable  Sample Size Raw Leptin Log-Leptin Main Effect AW x S Interaction 




Increases 19 192.72 (240.58) 4.60 (1.26) 
.900 
.033* 
Decreases 20 106.31 (156.71) 3.85 (1.60) 
Unchanged 72 113.16 (156.30) 3.86 (1.58) 
Sex 
Males 51 54.36 (63.95) 3.15 (1.54) 
< .001** 
Females 60 188.54 (211.59) 4.70 (1.16) 
Covariates 
Age (years) - - - .133 - 
BMI (kg/m2) - - - < .001** - 
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Independent samples t tests were performed to investigate Sex differences for the 
additional measures (Table 3). Waist circumference did not differ significantly between sexes 
(t(31) = -.64, p = .528, partial η2 = .013). Females reported more Restrained eating 
behaviours (M = 2.83, SD = 1.03) than males on the DEBQ (M = 1.72, SD = .64; t(31) = 3.45, 
p = .002, partial η2 = .278). Females also reported more frequent instances of Emotional 
eating (M = 2.93, SD = 1.11) than males (M = 2.02, SD = .93; t(31) = 2.43, p = .021, partial η2 
= .160). However, Sensitivity to external food cues was similar between sexes. 
Eight (24%; all female) of the 33 depressed participants in the sub-analysis met the 
YFAS criteria for food addiction. The Loss of control subscale was higher in females (M = 
.25, SD = .444) than males (M = .00, SD = .000; t(31) = 2.52, p = .021, partial η2 = .116). The 
Large amounts of time spent acquiring food subscale was also higher in females (M = .40, SD 
= .50) than males (M = .08, SD = .28; t(31) = 2.37, p = .024, partial η2 = .126). Females 
reported higher scores than males for Giving up important activities for the sake of acquiring 
food (M = .45, SD = .51, versus M = .08, SD = .28; t(31) = 2.71, p = .011, partial η2 = .157) 
and Withdrawal symptoms (M = .45, SD = .51 versus M = .08, SD = .28; t(31) = 2.71, p = 
.011, partial η2 = .157). Females had a higher total number of symptoms on the Food 
addiction symptom count (M = 3.50, SD = 1.82) than males (M = 1.92, SD = 1.26; t(31) = 
2.94, p = .006, partial η2 = .193). No further differences for the YFAS subscales between 










Table 5:  
Means, standard deviations and symptom endorsement rates for the eating measures and 
biometrics in a subset of depressed participants, by Sex (total n = 33; MDD only). 
 
Scale  Male Female p Endorsement 
  Mean (SD) Mean (SD)  % 
 Sample Size (n) 13 20 - -   
Biometrics Waist Circumference (cm) 92.54 (13.70) 88.36 (18.89) .528 -  - 
DEBQ Restrained 1.72 (.64) 2.83 (1.03) .002* - 
 Emotional 2.02 (.93) 2.93 (1.11) .021* - 
 External Cues 3.03 (.82) 3.34 (.72) .257 - 
YFAS Loss of Control .00 (.00) .25 (.44) .021* 15.2% 
 Inability to Cut Down 1.00 (.00) .85 (.37) .083 91% 
 Large amounts of Time .08 (.28) .40 (.50) .024* 27.3% 
 Giving up Activities .08 (.28) .45 (.51) .011* 30.3% 
 Continued Use Despite Issues .38 (.51) .50 (.51) .530 45.5% 
 Tolerance to Increased Food .31 (.48) .60 (.50) .107 48.5% 
 Withdrawal Symptoms .08 (.28) .45 (.51) .011* 30.3% 
 Symptom Count 1.92 (1.26) 3.50 (1.82) .006* - 
 
Note: DEBQ = Dutch Eating Behaviours Questionnaire, YFAS = Yale Food Addiction Scale. 
YFAS subscales are scored dichotomously and occur between 0.00 and 1.00. * a < .05. 
 
Waist circumference was positively correlated with weight (r(27) = .900, p < .001), 
BMI (r(27) = .874, p < .001) and diastolic blood pressure (r(27) = .413, p = .032). Log-leptin 
values correlated positively with waist circumference (r(25) = .510, p = .009) and BMI (r(25) 
= .549, p = .004), and correlated negatively with heart rate (r(25) = -.404, p = < .001). Log-
leptin values were also positively correlated with DEBQ Restrained eating (r(25) = .403, p = 




This is one of the first studies to examine leptin in relation to increased weight and 
appetite in MDD. A significant interaction effect between appetite/weight categories and sex 
was observed with respect to plasma leptin levels. Females with increased or stable 
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appetite/weight had higher leptin levels than those with reduced appetite/weight; however the 
opposite effect occurred for males, whereby males with decreased appetite/weight had higher 
leptin than those with increased or stable appetite/weight. These effects were present with 
correction for age and BMI. Since leptin has a fundamental role as an appetite suppressant 
(e.g. Elmquist et al., 1998), the higher leptin levels in males with decreased appetite/weight is 
consistent with normal leptin regulation. However, higher leptin levels in females with 
increased appetite/weight may be consistent with an interpretation of leptin resistance, a 
condition which is characterised by chronically elevated leptin levels and decreased leptin 
sensitivity (Pan et al., 2014). It is possible that the female participants who reported 
appetite/weight increases have become desensitised to endogenous signals regarding stores of 
body fat. As such, they continue to experience high levels of hunger despite higher levels of 
circulating leptin. This may be coupled with continuing to eat as a coping strategy for any 
physiological and psychological stress they are experiencing, with certain foods dampening 
HPA activity (Dallman et al., 2003; Ulrich-Lai, 2016).  
Leptin levels did not differ significantly between depressed and non-depressed 
participants in the current study. Further, no significant relationships between leptin levels 
and depression, anxiety or stress scores were present. Previous research has identified 
inconsistent results regarding leptin levels in MDD; some studies report increased leptin 
levels in depressed mood (Antonijevic et al., 1998; Morris et al., 2012), whereas others report 
lower or equivalent leptin levels in depressed participants versus controls (Carvalho et al., 
2014; Westling et al., 2004; Atmaca et al., 2003; Häfner et al., 2012; Ozsoy et al., 2014). 
Symptom profiles present heterogeneously in MDD, and previous studies did not specifically 
analyse leptin levels as a function of increased or decrease weight and appetite. Also, despite 
previous literature linking leptin to depressed mood (e.g. Westling et al., 2004; Morris et al., 
2012), the current results, in combination with previous studies, indicate that leptin may be 
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linked to sex-specific symptoms and pathophysiology of MDD (Lu, 2007), as opposed to the 
disorder as a whole. 
A clear overall sex difference in terms of plasma leptin levels was observed in all 
analyses, with female participants having higher plasma leptin levels than males, irrespective 
of MDD or appetite/weight change status. This is consistent with previous findings of a 
sexual dimorphism in leptin studies (e.g. Antonijevic et al., 1998; Rubin et al., 2002). 
Females tend to store more body fat for reproductive purposes (Blaak, 2001) and given a 
certain BMI, females are likely to have a higher percentage of body fat than males. As leptin 
secretion is proportional to adipose tissue mass (Maffei et al., 1995), females may have 
higher circulating leptin levels. Higher leptin levels and body fat percentages may act as a 
risk factor for weight gain in depressed females, and may perhaps explain why females are 
more prone to weight gain in MDD (Sutin & Zonderman, 2012; Grundy et al., 2014). 
Increased weight gain further represents a risk factor for other associated health risks in 
MDD, including cardiovascular disease and metabolic syndrome (Cassano & Fava, 2002; 
Penninx et al., 2013). As such, higher leptin levels may also represent a risk factor for these 
conditions, particularly in depressed females; however further longitudinal research is needed 
to explore the time course of these factors. 
Exploratory analysis of problematic eating behaviours and food addiction in a subset 
of depressed participants provided promising evidence. To our knowledge, relationships 
between leptin, MDD, problematic eating behaviours and eating addiction have not been 
previously reported. In the current study, instances of these problematic eating behaviours, 
including emotional and restrained eating, were consistently higher in depressed females 
compared to depressed males. These results indicate that these behaviours may represent sex-
specific coping mechanisms for depressed mood, which are also linked to hormone levels. 
Further, while depressed mood has previously been associated with increased emotional 
eating and food intake in response to food cues (van Strien et al., 2016; Sevincer et al., 2017), 
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the current study is the first to identify a direct link between MDD, leptin levels and 
problematic eating behaviours, including eating addiction. Despite the small sample size for 
the subset analysis, which limited the power to detect effects, plasma leptin was positively 
correlated with restrained and emotional eating. This may provide further evidence of leptin 
resistance in MDD, given that there were higher instances of food consumption and related 
behaviours despite the presence of equivalent leptin levels. In addition, approximately one 
quarter of depressed participants in the sub-analysis, all females, met the YFAS criteria for 
food addition, double the prevalence rates reported in non-clinical samples, and equivalent to 
that reported in obese samples (Meule & Gearhardt, 2014). This effect relating to food 
addiction has not, to our knowledge, been previously examined in a depressed sample. This 
suggests that food addiction may be a more common problem in MDD than previously 
realised. However, further research is needed to determine whether the role of leptin is causal 
or is a result of other mechanisms. 
Overall, the results of the current study suggest that leptin is related to sex-specific 
weight changes and problematic eating behaviours in MDD, even after controlling for BMI. 
Leptin levels were higher in female participants with increased appetite or weight gain, 
however this pattern was the opposite in males, who showed higher leptin with decreased 
appetite or weight loss. Leptin levels were positively correlated with measures of comfort 
eating and loss of control in food consumption. These results provide further support for 
leptin dysregulation in problematic eating behaviours in MDD that differs by sex. Leptin 
resistance may be a factor in appetite and weight dysregulation, particularly in females, and 
problematic eating behaviours in MDD. Further elucidation of the pathways between 
depression, health indicators and problematic eating behaviours could assist in the 
development of early interventions and preventative measures for individuals at risk of 
weight gain and associated chronic disease due to MDD. Research aimed at identifying 
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interventions to treat leptin resistance is emerging (Pan et al., 2014), which in future may be 
of value in assisting in reducing the risk of weight gain for depressed individuals. 
There are several limitations to the current study. Participants were not required to 
fast prior to blood collection, and diets were not controlled for. Previous leptin studies have 
used fasting and non-fasting protocols, and this should be considered when interpreting the 
results. Additional potential confounding variables, such as physical activity, were not 
controlled for, and should be considered for future studies. Further, the sub-investigation of 
food addiction and eating behaviour in relation to leptin was exploratory and conducted for 
only 33 participants. While these results are promising and showed that problematic eating 
behaviours were linked to leptin levels, larger studies with control participants are needed to 
investigate the predictive value of leptin and other hormones in relation to appetite and 
weight dysregulation. This may further serve as potential modifiable risk factors or points for 
early intervention in depression or obesity treatment. 
In conclusion, the current study provides new insights into the relationships between 
leptin, problematic eating behaviours, weight gain and MDD. In particular, the results 
suggest a possible role of leptin resistance in problematic eating behaviours in MDD, 
particularly in females. This highlights the need for further, longitudinal, research evaluating 
the temporal relationships between these variables and the role of leptin and leptin resistance 
as potential risk factors for weight gain and associated cardiovascular and metabolic health 
risks in subsets of individuals with MDD. This may lead to opportunities for early 
interventions aimed at preventing weight gain in at-risk individuals with MDD, and help to 
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